SUMMARY
INTRODUCTION
The transcription factor ER81 belongs to the family of ETS proteins that are characterized by a conserved, ~85 amino acids-long, DNA-binding ETS domain and perform many essential functions in homeostasis, signaling response and development (1) (2) (3) (4) . In addition to its ETS domain, ER81 possesses three further functional domains, an N-terminal and a C-terminal transactivation domain as well as a central inhibitory domain that regulates both transactivation domains (5) . Gene transcription mediated by ER81 is strongly stimulated by mitogen-activated protein kinases (MAPKs) 1 , which involves phosphorylation of ER81 at multiple sites (5, 6) .
Furthermore, ER81 is stimulated by the cAMP-dependent protein kinase A (PKA), albeit it is at present unknown whether ER81 is directly phosphorylated by PKA in vivo and how this may affect its ability to upregulate gene transcription (7) .
Expression of ER81 is both developmentally and tissue-specifically regulated. For instance, high levels of ER81 expression are detectable in the adult brain, heart or lung, whereas very little is found in liver or skeletal muscle (1, 8) . Moreover, ER81 expression is undetectable during early embryogenesis, yet at later stages is observable at various sites in the embryo, including the central nervous system, eye, heart, lung, salivary gland, kidney and pituitary gland (9, 10 ). An Coimmunoprecipitation -Transiently transfected 293T cells were either lysed in 0.5x
Frackelton-buffer (for α-Myc immunoprecipitation) or in 0.25x Frackelton-buffer plus 0.1% SDS (for α-HA immunoprecipitation) at 4°C. In addition, the following reagents were added to the lysis buffer: 10 µg/ml leupeptin, 2 µg/ml aprotinin, 1 µg/ml pepstatin A, 1 mM PMSF, 0.5 mM Na 3 VO 4 , 0.2 mM DTT. Otherwise, the immunoprecipitations were performed as described above, except that the protein A-agarose beads were washed four-times in lysis buffer. Finally, beads were boiled in Laemmli sample buffer and subjected to SDS-PAGE. Subsequently, semidry Western blotting was performed, and blots were probed with α-HA or α-Myc monoclonal antibodies followed by goat anti-mouse antibodies coupled to horseradish peroxidase. Blots were developed utilizing enhanced chemiluminescence.
GST Pull-down Assay -293T cells transiently transfected with 5 µg of HA-tagged rat RSK1 expression vector were released from the culture dish with 600 µl of 40 mM Hepes pH 7.4, 10 mM EDTA, 150 mM NaCl. After pelleting (2 min, 960 x g), cells were resuspended in 100 µl of
Frackelton-buffer supplemented with 10 µg/ml leupeptin, 2 µg/ml aprotinin, 1 µg/ml pepstatin A, 1 mM PMSF, 0.5 mM Na 3 VO 4 , 2 mM DTT and lysis was allowed to proceed for 45 min on ice. Debris was removed by centrifugation (10 min, 20800 x g). 10 µl of this cell lysate were mixed with ~2 µg glutathione S-transferase (GST) fusion protein bound to glutathione-agarose beads in 600 µl of 20 mM Hepes pH 7.4, 25 mM NaCl, 0.01% Tween-20, 10 µg/ml leupeptin, 2 µg/ml aprotinin, 1 µg/ml pepstatin A, 0.2 mM PMSF, 0.1 mM Na 3 VO 4 , 2 mM DTT. After 2 h tumbling at 4°C, beads were pelleted (1 min, 960 x g) and washed three times. Then, bound RSK1 was detected by α-HA Western blotting.
Luciferase Assay -RK13 cells were transfected with 1 µg of reporter luciferase plasmid and indicated amounts of mammalian expression plasmids. Lysis of cells and determination of luciferase activity was essentially done as described (31) .
Electrophoretic Mobility Shift Assay -293T cells were transiently transfected with 250 ng ER81 2-477 expression vector and, where indicated, cotransfected with 0.1 µg BXB, 5 µg RSK1 or 2 µg PKA expression plasmid. RK13 cells were transiently transfected with 1000 ng of ER81 and 2 µg of PKA expression plasmids employing Fugene 6 (Roche) transfection reagent. 36 h after transfection, cells were sprayed off the plates with 600 µl of 40 mM Hepes pH 7.4, 10 mM EDTA, 150 mM NaCl and transferred into a 1.5 ml tube. After centrifugation (2 min, 960 x g), the cell pellet was resuspended on ice in 200 µl of Frackelton-buffer supplemented with 10 µg/ml leupeptin, 2 µg/ml aprotinin, 1 µg/ml pepstatin A, 1 mM PMSF, 0.5 mM Na 3 VO 4 , 2 mM DTT. After 1 h incubation on ice under occasional mixing, the debris was removed by centrifugation (10 min, 20800 x g, 4°C) and the resulting supernatant frozen in liquid nitrogen and stored at -80°C. 0.05 or 0.15 µl of this cell extract was incubated with 32 P-labeled, doublestranded E74 oligonucleotide in 10 µl of 20 mM Hepes pH 7.4, 25 mM NaCl, 0.5 mM EDTA, 12% glycerol, 0.01% Tween-20, 2 mM DTT, 0.1 µg/µl bovine serum albumin, 0.05 µg/µl poly(dI-dC)*poly(dI-dC) (sonicated to an average length of 400 bp). Samples were incubated for
To obtain 32 P-labeled, double-stranded E74 oligonucleotide, 1 µg of respective sense (5'-AGCTTCTCTAGCTGAATAACCGGAAGTAACTCATCG-3') and antisense (5'-TCGACGATGAGTTACTTCCGGTTATTCAGCTAGAGA-3') primers were mixed in a total volume of 100 µl containing 5 mM Tris-HCl pH 7.4, 0.5 mM EDTA, 100 mM NaCl, boiled for 10 min and then slowly cooled down to room temperature. Labeling of hybridized primers was done by filling-in overhanging ends with Klenow enzyme in the presence of α-32 P-dATP.
RESULTS
Interaction between ER81 and RSK1 -Previously, we have shown that cofactors of ER81, the homologous proteins CBP and p300, form a complex with ER81 and an unidentified protein kinase in vivo (32) . It has also been reported that CBP/p300 associate with the protein kinase RSK1 (33) . Thus, we speculated that the unidentified protein kinase may be RSK1 and that RSK1 and ER81 also interact with each other. Therefore, we investigated their in vivo interaction in 293T cells by coimmunoprecipitation assays. To that end, we coexpressed Myctagged ER81 with HA-tagged RSK1, performed an immunoprecipitation with α-HA antibodies and then analyzed the precipitate for the presence of Myc-tagged ER81 by α-Myc Western blotting. As shown in Fig. 1A , ER81 indeed coimmunoprecipitated with RSK1. Similarly, the reciprocal coimmunoprecipitation assay (α-Myc immunoprecipitation followed by α-HA Western blotting) demonstrated an in vivo interaction between RSK1 and ER81 (Fig. 1B) .
We also studied the interaction of RSK1 with ER81 in vitro by GST pull-down assays.
Whereas RSK1 did not bind to the GST moiety itself, it interacted with full-length ER81 fused to GST (see GST-ER81 2-477 , Fig. 1C ); comparable amounts of GST and GST-ER81 2-477 were employed as judged by Coomassie blue staining of a protein gel (Fig. 1D ). In conclusion, ER81
and RSK1 can interact both in vitro and in vivo.
In vivo phosphorylation of ER81 is enhanced upon complex formation with CBP/p300 (32).
One explanation for this could be that CBP/p300 promote the interaction between RSK1 and ER81. In order to test this hypothesis, we coexpressed RSK1 and ER81 together with p300 in 293T cells. Indeed, more RSK1 coimmunoprecipitated with ER81 in the presence of p300 than in its absence (Fig. 1E ), indicating that p300 promotes the in vivo association between ER81 and RSK1.
To further characterize the interaction between ER81 and RSK1, we coexpressed different ER81 truncations with RSK1 and performed coimmunoprecipitation assays. As shown in Fig. 2 , ER81 182-477 is capable of interacting with RSK1 to a similar extent as the full-length ER81 protein. However, further truncation of N-terminal amino acids in ER81 249-477 and ER81 abolished the interaction with RSK1. Thus, amino acids within the inhibition domain (amino acids 182-249) of ER81 are important for the interaction with RSK1.
Similarly, we studied the importance of ER81 C-terminal amino acids. Whereas deletion of the C-terminal activation domain had no effect on the ability of ER81 to interact with RSK1
( Fig. 2 , see ER81 2-429 ), truncating amino acids beyond the ETS domain in ER81 1-334 and ER81 prevented an interaction of ER81 with RSK1. Thus, amino acids 333-429 are also required, but not sufficient (see ER81 in Fig. 2 ) for the interaction of ER81 with RSK1. Altogether, binding of RSK1 to ER81 occurs within ER81 amino acids 182-429 that encompass the central inhibitory domain and the DNA-binding domain of ER81. Interestingly, ER81 amino acids 249-429 are also required for the interaction with CBP/p300 (32), yet p300 does not compete with RSK1 for binding to ER81 since p300 augments the complex formation between RSK1 and ER81 (see Fig. 1E ). Thus, different interaction surfaces within amino acids 249-429 appear to be involved in binding to CBP/p300 and RSK1, allowing simultaneous binding of CBP/p300 and RSK1 to ER81.
Stimulation of ER81 Transcriptional Activity by RSK1 -MAPK-activated ER81 has been
shown to stimulate a luciferase reporter gene driven by three copies of the E74 site, a paradigmatic binding site for ETS proteins (5, 34, 35) . Thus, we analyzed the effect of RSK1 on ER81-dependent transcription from the E74 site in RK13 cells. As reported before (5), the ERK-MAPK activator BXB, a constitutively active form of the Raf-1 kinase (36), strongly enhanced ER81-dependent transcription (Fig. 3A) , whereas RSK1 on its own had only a slight effect, most likely because it has not been activated by ERK-MAPKs. Indeed, upon overexpression of BXB, leading to the activation of ERK-MAPKs, coexpression of RSK1 led to >2.5-fold enhancement of ER81-dependent transcription compared to BXB alone. In the absence of overexpressed ER81, transcription was moderately increased by BXB, probably due to endogenous ER81 or related ETS proteins, and additional RSK1 coexpression had only a slight effect (Fig. 3A) .
Furthermore, elevation of BXB-triggered ER81-mediated transcription was dependent on RSK1 kinase activity, since the non-activatable S364A mutant of RSK1 (29) failed to cooperate with BXB ( Fig. 3B ). Also, a control Western blot revealed that RSK1 or BXB expression did not increase ER81 protein levels (Fig. 3C ).
Next, we wished to study how RSK1 affects the activation of a natural ER81 target gene promoter. Previously, it has been shown that the interstitial collagenase (m a t r i x metalloproteinase-1) promoter is regulated by ER81 and MAPKs (6) . Utilizing a respective luciferase reporter construct, we observed that RSK1 elevates luciferase levels in the presence of BXB and ER81 by >4.5-fold, indicating that BXB and RSK1 synergize to stimulate ER81-dependent interstitial collagenase transcription (Fig. 3D) . Altogether, our data suggest that RSK1, upon activation by ERK-MAPKs, stimulates ER81-dependent transcription. (38), could all increase the ability of RSK1 to phosphorylate a slightly different GST-ER81 fusion protein than used above, GST-ER81 182-334 (Fig. 4C) . As a control, we also utilized the inactivatable RSK1-S364A mutant, which was unable to significantly phosphorylate GST-ER81 182-334 (Fig. 4C) . Phosphoamino acid analysis of GST-ER81 182-334 phosphorylated by RSK1 revealed that phosphorylation occurred on serine, but not on threonine or tyrosine residues (Fig. 4D) .
Phosphorylation of ER81 by RSK1 in vitro
Mapping of RSK1 Phosphorylation Sites -In order to determine the RSK1 phosphorylation sites in ER81, we scanned ER81 amino acids 182-339 for the RSK consensus site, Arg/Lys-XaaArg-Xaa-Xaa-Ser/Thr. Furthermore, we took into account that RSK1 can still phosphorylate serine/threonine residues not preceded by an arginine or lysine residue at position n-5, especially when an additional arginine residue is present at position n-2 or n-4 (39). We noted three potential RSK1 sites in ER81 182-339 : Phe-Arg-Arg-Gln-Leu-Ser 191 , Tyr-Gln-Arg-Gln-Met-Ser 216 and Tyr-Gln-Arg-Arg-Gly-Ser
334
. Thus, we utilized GST-ER81 182-339 and serine to alanine mutations thereof in in vitro kinase assays with RSK1. Mutation of Ser334 to alanine greatly reduced the amount of 32 P-incorporation, whereas joint mutation of Ser191 and Ser216 led to a less severe reduction in phosphorylation by RSK1 (Fig. 5A ). Mutation of all three serine residues to alanine abrogated in vitro phosphorylation of GST-ER81 182-339 by RSK1. These results suggest that the main in vitro RSK1 phosphorylation site is Ser334, but that additional phosphorylation occurs also on Ser191 and/or Ser216.
Next, we metabolically labeled ER81 in 293T cells with 32 The fact that more than one phosphopeptide corresponding to Ser334 phosphorylation has been observable results from incomplete trypsin digestion of ER81 at adjacent arginine residues at position 331 and 332, and possibly also from oxidation (30). Altogether, these results suggest that RSKs, upon activation by ERK-MAPKs, phosphorylate Ser191 and Ser216, but not Ser334, to a significant degree in vivo.
Impact of RSK1 Phosphorylation on ER81 Activity -In order to determine the impact of RSK1 phosphorylation on ER81 function, we first analyzed whether RSK1-mediated phosphorylation affects its DNA-binding activity. To that end, we performed electrophoretic mobility shift assays with a 32 P-labeled E74 oligonucleotide, to which ER81 specifically binds (5), and lysates from cells that were transfected with ER81. As shown in Next, we tested whether RSK1 phosphorylation can affect the transactivation potential of ER81. Mutation of the RSK1 phosphorylation sites Ser191 and Ser216 to alanine slightly reduced the ability of ER81 to activate the interstitial collagenase promoter upon stimulation with BXB or the combination of BXB and RSK1 (Fig. 6B ). On the other hand, mutation of Ser334 to alanine had no effect; this was to be expected since RSK1 does not significantly phosphorylate Ser334 in vivo. Four in vivo MAPK phosphorylation sites have been identified in ER81, Ser94, Thr139, Thr143 and Ser146 (6) , and mutation of these sites to alanine slightly reduced ER81-dependent transcription (see mMAPK mutant in Fig. 6B ). In contrast, combined mutation of the four MAPK phosphorylation sites and Ser191/Ser216 strongly reduced ER81's ability to activate the interstitial collagenase promoter in the presence of RSK1 and/or BXB; additional mutation of Ser334 had no further impact. Similar results were also obtained upon studying the activation of E74 site-driven transcription by ER81 (data not shown). In conclusion,
RSK1 Targets the Coactivators CBP/p300 -Mutation of the in vivo RSK phosphorylation
sites, Ser191 and Ser216, did reduce but not abrogate the ability of RSK1 to stimulate ER81-dependent activation of the interstitial collagenase promoter (see Fig. 6B ). This may be due to the fact that RSK1 also activates ER81-associated proteins such as its cofactors, the homologous proteins CBP and p300. As such, we first analyzed whether CBP and p300 are involved in ER81-dependent transcription from the interstitial collagenase promoter in RK13 cells.
To that end, we tested whether p300 overexpression would augment ER81-and RSK1-mediated transcription.
However, p300 overexpression did not enhance ER81-dependent transcription, but rather slightly reduced it (Fig. 7A ). This would be consistent with the fact that the amount of CBP and p300 is not limiting in the cell line used, and that overexpression of p300 leads to squelching, the sequestration of factors necessary for ER81-dependent transcription by an excess of p300.
On the other hand, if ER81-mediated transcription is dependent on CBP and p300, depleting RK13 cells of endogenous CBP and p300 should reduce ER81-mediated transcription. One way of depleting the available pool of endogenous CBP and p300 is by overexpression of the adenoviral protein E1A (41, 42) . Indeed, E1A suppressed transcription mediated by ER81 under all conditions tested (Fig. 7A) . Further, an E1A mutant, E1A-∆2-36 (43) , that is impaired in sequestering CBP and p300, did not affect ER81-dependent transcription. These results strongly suggest that CBP and p300 are required for maximal transcription elicited by ER81 and RSK1.
To test the hypothesis that RSK1 may also stimulate CBP function, the N-terminal (amino acids 1-451) and the C-terminal (amino acids 1891-2441) transactivation domains of CBP were fused to the GAL4 DNA-binding domain and their activities assessed with a GAL4 binding sitedriven luciferase reporter. As reported before (44) , BXB was capable to stimulate both transactivation domains of CBP (Fig. 7B) . Importantly, RSK1 coexpression with BXB led to an even higher degree of transactivation. These results suggest that RSK1 not only furthers ER81-dependent transcription by directly phosphorylating ER81, but additionally by activating CBP/p300.
Phosphorylation of ER81 by PKA -Since PKA is related to RSK1 and since PKA has been reported to activate ER81-dependent transcription (7), we recapitulated in vitro kinase assays with PKA. Similar to RSK1, PKA solely phosphorylated ER81 within amino acids 182-339 ( Fig.   8A ) on Ser191/Ser216 as well as on Ser334 (Fig. 8B ).
Next, we analyzed whether PKA can induce phosphorylation of ER81 in vivo. To that end, RK13 cells transiently transfected with Myc-tagged ER81 were metabolically labeled with 32 Porthophosphate, ER81 immunoprecipitated with α-Myc antibodies and the incorporated radioactivity revealed by autoradiography after Western blotting. Coexpression of the catalytic subunit of PKA strongly stimulated the in vivo phosphorylation of ER81 (Fig. 8C ). In addition, the S191/216A mutant was slightly less phosphorylated than wild-type ER81 in the presence of PKA, whereas phosphorylation of the S334A mutant was significantly reduced. Furthermore, the triple alanine mutant S191/216/334A was no longer phosphorylated in the presence of PKA.
These observations indicate that PKA phosphorylates Ser191/216 and Ser334 in vivo, with Ser334 being the preferential in vivo phosphorylation site.
Impact of PKA Phosphorylation on ER81 Activity -The ability of PKA to influence ER81
DNA-binding was assessed in electrophoretic mobility shifty assays with the 32 P-labeled E74
oligonucleotide. In contrast to RSK1, coexpression of PKA with ER81 dramatically reduced the DNA-binding activity of ER81 (Fig. 9 ). Similar to wild-type ER81, the S191/216A mutant displayed severely reduced DNA-binding upon PKA stimulation, whereas the S334A and the S191/216/334A mutants were not diminished in their ability to bind to the E74 oligonucleotide.
These results suggest that phosphorylation on Ser334, which is at the N-terminal border of the ETS DNA-binding domain (see Fig. 2 for a sketch of ER81), negatively regulates DNA-binding by ER81.
In addition, we assessed the impact of PKA phosphorylation on ER81 transcriptional The S191/216A mutant was always slightly more active than wild-type ER81 upon PKA stimulation (Fig. 10A) , consistent with our previous observation that phosphorylation of ER81
solely on Ser191 and Ser216 reduces its transactivation potential (32) . In contrast, the S334A mutant was more active at lower concentrations of expression plasmid, but at 1000 ng of expression vector was 3.7-fold less active than wild-type ER81 (Fig. 10A) . At high concentrations of ER81, the interstitial collagenase promoter will be occupied to nearly the same degree by wild-type ER81 and the S334A mutant in the presence of PKA. Thus, the difference in luciferase activity observed is solely a reflection of a different transactivation potential, indicating that Ser334 phosphorylation enhances it (see Fig. 10B ). In contrast, at low concentrations of ER81, the reduction in DNA-binding activity caused by Ser334 phosphorylation prevents efficient DNA-binding of the wild-type, but not of the S334A mutant ER81 molecule, which is why the wild-type is now less capable of activating the interstitial collagenase promoter than the S334A mutant. Similar results as with the interstitial collagenase promoter were obtained with the E74 site-driven luciferase construct (data not shown).
In order to study the impact of Ser334 phosphorylation on transcription independently of ER81 binding to DNA via its ETS domain, we fused full-length ER81 to the GAL4 DNAbinding domain and assayed this chimera with a GAL4 binding site-driven luciferase reporter.
As predicted from our experiments above, mutation of Ser334 to alanine reduced the ability of GAL4-ER81 to enhance transcription upon PKA stimulation (Fig. 10C) . In contrast, the S191/216A mutant behaved similarly as wild-type GAL4-ER81. These data corroborate the notion that Ser334 phosphorylation indeed enhances the transactivating capability of ER81.
Finally, we ascertained that the differences seen between wild-type and S334A ER81 at high concentrations (1000 ng expression vector) were not compromised by limiting amounts of CBP/p300 or incomplete phosphorylation of ER81. First, we established that the enhancement of ER81 activity by PKA is dependent on CBP/p300. Indeed, E1A, but not E1A-∆2-36, suppressed transcription mediated by ER81 and PKA (Fig. 10D) , indicating that CBP/p300 are involved in the activation of ER81 by PKA. Furthermore, overexpression of p300 did not augment ER81
activity, but rather squelched it (Fig. 10D) , indicating that endogenous CBP/p300 levels are 10E ). If phosphorylation of wild-type ER81 on Ser334 would be significantly substoichiometrically, one would expect at least some binding of ER81, as was observed with wildtype ER81 in the absence of PKA (see Fig. 9 ). Therefore, we conclude that phosphorylation of ER81 occurred stoichiometrically even at 1000 ng of ER81 expression vector, indicating that PKA amounts were not limiting. 
DISCUSSION
In this report, we have identified RSK1 as an ER81-associated protein kinase that phosphorylates ER81 and enhances the transactivation potential of both ER81 and its cofactors CBP/p300. Furthermore, we have uncovered PKA phosphorylation sites in ER81 and unraveled how this affects DNA-binding as well as transactivation mediated by ER81.
RSK1 and PKA are related serine/threonine protein kinases (19) . Both kinases phosphorylate basophilic motifs, characterized by an arginine at position n-3 and an arginine or lysine at position n-5 in case of RSK1, and in case of PKA by arginines at position n-3 and n-2 with respect to the phosphorylated serine/threonine residue (39, 45) . However, deviations from these strict consensus motifs have often been observed; in particular, many PKA sites have only one arginine at position n-3, and the arginine/lysine residue at n-5 is not essential for RSK1
phosphorylation. As such, the ER81 amino acids Phe-Arg-Arg-Gln-Leu-Ser 191 , Tyr-Gln-ArgGln-Met-Ser 216 and Tyr-Gln-Arg-Arg-Gly-Ser 334 all conform to the minimal requirements for being both RSK1 and PKA phosphorylation sites. However, whereas RSK1 readily phosphorylates Ser191, Ser216 and Ser334 in vitro, it appears to only phosphorylate Ser191 and Ser216 in vivo, indicating that access to Ser334 is restricted in full-length ER81 in vivo. One potential reason for this could be ER81 interacting proteins, including CBP/p300 or RSK1 itself, which prevent the N-terminal kinase domain of RSK1 from phosphorylating Ser334. In contrast, maybe due to its smaller size, PKA has access to Ser334 and can phosphorylate Ser334 both in vitro and in vivo. Further, Ser334 is even more efficiently phosphorylated by PKA in vivo than Ser191 and Ser216, possibly because only Ser334 is part of an optimal PKA target site, Arg-Arg-
Xaa-Ser (45).
Phosphorylation of ER81 solely confined to Ser191/216 has been shown to inhibit ER81 function (32) , explaining why the S191/216A mutant is more active than the wild-type upon PKA phosphorylation. However, when additional phosphorylation occurs at the MAPK sites (Ser94, Thr139, Thr143 and Ser146), phosphorylation of Ser191/216 actually promotes ER81-dependent transcription (6), which is why the S191/216A mutant of ER81 is less active than the wild-type in the presence of RSK1 and/or BXB. Consistent with RSKs' inability to phosphorylate Ser334 in vivo, mutation of Ser334 to alanine has no effect on the transactivation potential of ER81 upon stimulation of the ERK-MAPK pathway.
In contrast to RSK1, PKA readily phosphorylates Ser334 in vivo, thereby reducing ER81's DNA-binding activity; a similar reduction of DNA-binding activity has been observed upon PKA phosphorylation of hepatocyte nuclear factor-4 and the ER81-related protein ERM within their DNA-binding domains (46, 47) . Consequently, at low intracellular concentrations of ER81, promoter occupancy by the S334A mutant of ER81 is much higher than for wild-type ER81, resulting in more transcription with the S334A mutant than with wild-type ER81. However, we observed that this does not hold true at high intracellular concentrations of ER81. If the intracellular concentration of ER81 is very high, the law of mass action predicts that even ER81 phosphorylated on Ser334 will effect a high degree of promoter occupancy. Therefore, at high concentrations of ER81, the different abilities of wild-type ER81 and of the S334A mutant to bind to DNA becomes functionally irrelevant. As such, one will observe only a difference in transactivation potential, and this is smaller for the S334A mutant than for wild-type ER81.
Thus, phosphorylation of ER81 on Ser334 has a dual function: reducing the DNA-binding ability of ER81, but enhancing its transactivation potential.
Normal intracellular ER81 concentrations will probably never be as high as achieved upon transfection of 1000 ng of ER81 expression plasmid as utilized in Fig PKA can crosstalk with the ERK-MAPK pathway (Fig. 11) ER81 is highly expressed in the brain and also in the spinal cord, where it is required for the proper establishment of contacts between sensory and motor neurons (1, 8, 11, 59) . In neuronal cells, Ca 2+ influx through ion channels is a prominent way of relaying signals and memory formation. Ca 2+ influx can funnel into both the ERK-MAPK and the PKA signaling pathways (60) (61) (62) (63) (64) . Thereby, ER81 activity could be regulated by Ca 2+ in neuronal cells, which may be important for neuronal function and development.
ER81 has been implicated in the development of breast cancer, since it is a downstream target of HER2/Neu (6), a proto-oncoprotein known to be capable of inducing breast cancer (15, 16) , and since ER81 expression is even upregulated in HER2/Neu-overexpressing mammary tumors (13) . HER2/Neu is a receptor tyrosine kinase that can activate the Ras->Raf->MEK1/2->ERK-MAPK pathway, and therefore also RSKs. As such, RSK phosphorylation of ER81 may contribute to breast tumor formation upon HER2/Neu overexpression. Notably, ER81 may also be activated through RSKs in tumors characterized by oncogenic Ras mutations, one of the most commonly observed mutations in cancer cells. On the other hand, activation of PKA by cAMP may act either positively or negatively on cell proliferation (65). In MDA-MB231 breast cancer cells, for instance, the PKA stimulator oxytocin inhibits cell proliferation (66). It is tempting to speculate that one reason for this could be the reduction of ER81 DNA-binding activity induced by Ser334 phosphorylation, and accordingly the suppression of ER81 target gene activity.
In conclusion, we have unraveled how two distinct signaling pathways, the growth-factoractivated ERK-MAPK pathway and the neurotransmitter/hormone-activated PKA pathway, converge on the transcription factor ER81 and modulate its activity in a complex manner. This knowledge may help us to understand how ER81 functions during ontogenesis and carcinogenesis. 
ERK-MAPK

Growth Factors
RSK
PKA
Ca 2+
Neurotransmitters/ Hormones cell type-specific Figure 11 , Wu & Janknecht
